Barriers and Clinical Factors Influencing Outcomes of Older Children with Medulloblastoma in a Resource Limited Setting - Peru
Rosdali Díaz Coronado(Instituto Nacional de Enfermedades Neoplásicas), Diana S. Osorio(Nationwide Children's Hospital), Joseph Stanek(Nationwide Children's Hospital), James B. Reinecke(Michigan United), Eddy Hernández(Instituto Nacional de Enfermedades Neoplásicas), Ebert Torres Malca(Instituto Nacional de Enfermedades Neoplásicas), Raymundo Sernaque Quintana(Instituto Nacional de Enfermedades Neoplásicas), Luis Ojeda Medina(Instituto Nacional de Enfermedades Neoplásicas), William Quispe Valverde(Instituto Nacional de Enfermedades Neoplásicas), Sandro Casavilca‐Zambrano(Institute for Anthropological Research), Jonathan L. Finlay(The Ohio State University), Pamela García‐Corrochano Medina(Instituto Nacional de Enfermedades Neoplásicas), Sharon Chávez(Instituto Nacional de Enfermedades Neoplásicas), Yesenia Miranda Tunque(Instituto Nacional de Enfermedades Neoplásicas), Juan Garcia Leon(Instituto Nacional de Enfermedades Neoplásicas), Adela Heredia Zelaya(Instituto Nacional de Enfermedades Neoplásicas)
Cited by 1
Related Papers
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
|Nature Communications|2019|372
COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients
|Journal of Infection|2021|248
Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group.
|Journal of Clinical Oncology|1996|203
High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group.
|Journal of Clinical Oncology|1998|188